A PDF of The COPD-X Plan Version 2.30 Dec 2011
is now available.
Simply register to gain
access to the PDF.
O: Optimise function
| 
Appendix 1
Use and doses of long-term inhaled bronchodilator and glucocorticoids determined in response trials
|
Response |
Drug |
Dose (mcg) |
Frequency |
Delivery |
|
Improved airway function
|
beta-agonist |
|||
|
Salbutamol |
200mcg |
4-6-hourly |
MDI/spacer |
|
|
Terbutaline |
500mcg |
6-8-hourly |
DPI |
|
|
Salmeterol |
50mcg |
12-hourly |
MDI/DPI |
|
|
Formoterol |
12mcg |
12-hourly |
MDI/DPI |
|
|
Anticholinergic |
||||
|
Ipratropium |
40-80mcg |
6-8-hourly |
MDI/spacer |
|
|
Tiotropium |
18mcg |
24-hourly |
DPI |
|
|
Glucocorticoid |
Inhaled |
|||
|
Beclomethasone |
400-800mcg/day |
|
MDI/spacer |
|
|
Budesonide |
800-1600mcg/day |
|
DPI |
|
|
Fluticasone |
500-1000mcg/day |
|
MDI/DPI |
|
|
Ciclesonide |
80-320mcg/day |
|
MDI – spacer not recommended |
|
|
MDI=metered dose inhaler. DPI=dry powder inhaler. |
||||
| < Prev | Next > |
|---|
COPD-X Plan - Version 2.30 - December 2011
We comply with the HONcode standard for trustworthy health information: verify here.